Celanese (CE) Stock Could Be Below Fair Value On Joint Venture Sale News

Celanese has delivered a painful long run for shareholders, with the stock still well below past levels even as current valuation checks now lean cheap. That mix of weak 5 year returns and a high value score puts the focus squarely on whether the market is underpricing the business or rightly discounting its risks.

• Over the past 5 years, Celanese shares have fallen about 66.6%, which signals investors have heavily repriced the company.
• The planned sale of an additional 19% stake in the Nutrinova joint venture to Mitsui, expected to bring in roughly US$152 million, can support balance sheet repair, while any setback to deleveraging efforts may keep a lid on how much value investors are willing to assign to the equity.
• The high value score of 5 suggests the broader checks lean cheap relative to what the current share price implies.

The issue now is whether Celanese is genuinely undervalued after such a steep long term decline, or whether the current price already reflects a fair view of its prospects.

Spot opportunities in other potential deep value candidates by scanning our curated list of 31 high quality undervalued stocks.

Is Celanese a Bargain on Sales?

P/S suits Celanese because investors often look at revenue-based measures for cyclical chemicals where earnings can swing around. On this yardstick, Celanese trades on a P/S of about 0.5x, which is below both the chemicals industry average of roughly 1.1x and the broader peer group closer to 2.7x.

The fair P/S ratio that blends in Celanese specific traits such as size, margins and risk sits at about 1.1x, roughly double where the stock changes hands today. Despite the planned Nutrinova stake sale supporting debt reduction plans, the current revenue multiple still implies the market is pricing the business at a clear discount to what this tailored benchmark suggests.

On the P/S multiple, Celanese stock appears undervalued relative to both its own fair ratio and typical sector benchmarks.

See what the numbers say about this price — find out in our valuation breakdown.

The Celanese Narrative: What Would Justify Today's Price?

Narratives for Celanese pick up where the P/S puzzle leaves off, spelling out which combinations of future growth, profitability and earnings would need to unfold for the current share price to look materially higher or lower in hindsight. They sit on Simply Wall St's Community page and turn a single valuation output into a set of concrete assumptions, so you can watch over time whether the real business is actually matching the future that number is built on.

The community is split on Celanese, with one camp leaning into a recovery story and another warning that structural headwinds could keep a lid on the equity.

Bull case: 46% undervalued

"The accelerating global shift toward lightweight, high-performance polymers, especially for electric vehicles and next-generation electronics, is creating multiyear demand tailwinds..."

Read the full Bull Case to see why Celanese could be undervalued

Bear case: roughly fairly valued

"Ongoing oversupply and intense price competition in the chemicals market, particularly exacerbated by Chinese overcapacity and limited visibility into end market recovery, are projected to keep global acetyls and high-volume engineered materials prices depressed..."

Read the full Bear Case to see why Celanese could be overvalued

Do you think there's more to the story for Celanese? Head over to our Community to see what others are saying!

The Bottom Line

Celanese screens as undervalued on market multiples, with the P/S gap implying investors are still pricing in heavy caution around the business. The discount only closes if the market grows more comfortable with balance sheet repair and the earnings power behind those sales. For you, the key question is whether current fears about industry pressure and deleveraging linger or whether sentiment shifts enough for that revenue multiple to re rate closer to peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com